Roche delays acquiring Spark as regulatory review process continues
Category: #health  | By Mateen Dalal  | Date: 2019-05-16 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Roche delays acquiring Spark as regulatory review process continues

Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of the proposed $4.3 billion takeover.

As per credible source, Spark and Roche plan to refile their Premerger Notification and Report Forms in order to provide additional time to the government for the review. The acquisition is regulated by the antitrust Hart Scott Rodino Act, 1976.

In a joint statement, the companies have said they are actively working with the government to expediate the process. Spark and Roche did not disclose the specifics as to why the government needs additional time to review the deal. Roche did perceive that the acquisition could have been completed earlier, if the government granted early termination of waiting period, cites source.

Reportedly, Roche has said that the FTC (Federal Trade Commission) requires more time to complete the review.

For the record, Spark is the pioneering biotech company to commercialize a gene therapy for a genetic disease in the U.S. In December 2017, the Unites States Food and Drug Administration approved Spark’s Luxturna, a gene therapy for a rare genetic type of blindness. FDA Commissioner Scott Gottlieb said at the time of approval, that gene therapy will become a mainstream form of treating and maybe even curing various diseases.

Since the approval of Luxturna, Spark has been advancing a remarkable gene therapy treatment for Hemophilia A. Last August, the company released data that indicated a 97% response rate for reduced bleeding events in patients. The updated data was provided at American Society of Hematology meeting and it continues to exhibit strong response from the patients and has a strong safety profile, says the company. This is expected to supplement Roche’s hemophilia treatment, Hemlibra. Last year’s approval for a second indication has made Hemlibra the only available treatment for Hemophilia A.

Source credits: https://in.reuters.com/article/us-spark-m-a-roche/roche-pushes-back-spark-takeover-again-as-regulatory-review-drags-on-idINKCN1SK0GL

https://www.biospace.com/article/the-roche-acquisition-of-spark-hits-a-delay-due-to-regulatory-review-process/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

By Mateen Dalal

American chemical company DuPont de Nemours Inc. reportedly signed a definitive agreement to buy out Spectrum Plastics Group from AEA Investors, a U.S. based private equity firm. The acquisition will reinforce DuPont’s position in booming non-c...